Antibody-Drug Conjugates (ADCs): Purposefully Designed to Link Technology with Biology

Pfizer Oncology is investing in research to develop a broad ADC platform from a diverse toolkit of antibodies, linkers and cytotoxins. Each component is precisely selected based on our deep understanding of biological characteristics of the target tumor.

Click Here to Learn How ADCs Work
How ADCs Work

ADCs are designed to precisely deliver cytotoxins to cancer cells with potential to treat both solid tumors and hematologic cancers.

Click on each picture to see how.
How ADCs Work

ADCs are designed to precisely deliver cytotoxins to cancer cells with potential to treat both solid tumors and hematologic cancers.

Click on each picture to see how.

ADCs use a chemical linker to connect cytotoxins – such as chemotherapy – with an antibody.
How ADCs Work

ADCs are designed to precisely deliver cytotoxins to cancer cells with potential to treat both solid tumors and hematologic cancers.

Click on each picture to see how.

ADCs use a chemical linker to connect cytotoxins – such as chemotherapy – with an antibody.

This enables the ADC to target and bind to cell-surface proteins called antigens found preferentially on cancer cells...
How ADCs Work
ADCs are designed to precisely deliver cytotoxins to cancer cells with potential to treat both solid tumors and hematologic cancers.

Click on each picture to see how.

ADCs use a chemical linker to connect cytotoxins – such as chemotherapy – with an antibody.

This enables the ADC to target and bind to cell-surface proteins called antigens found preferentially on cancer cells...

...and time the release of its cell-killing drugs only after it has been internalized inside the cancer cell.
As a result, ADCs have the potential to selectively kill cancer cells and minimize side-effects for patients.

How ADCs Work
ADCs are designed to precisely deliver cytotoxins to cancer cells with potential to treat both solid tumors and hematologic cancers.

Click on each picture to see how.

- ADCs use a chemical linker to connect cytotoxins – such as chemotherapy – with an antibody.
- This enables the ADC to target and bind to cell-surface proteins called antigens found preferentially on cancer cells...
- ...and time the release of its cell-killing drugs only after it has been internalized inside the cancer cell.
- As a result, ADCs have the potential to selectively kill cancer cells and minimize side-effects for patients.